Catalyst Pharmaceuticals CEO equity converted in merger
Catalyst Pharmaceuticals President and CEO Richard J. Daly reported the disposition of 271,266 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A.
Rhea-AI Filing Summary
Catalyst Pharmaceuticals President and CEO Richard J. Daly reported the disposition of 271,266 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A.
All reported restricted stock units and stock options were cancelled and converted into cash rights based on the $31.50 merger price, with option payouts equal to the merger price minus the exercise price per share. After these transactions, no holdings of the reported awards remain.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Disposition: 2,889,805 shares
Disposition
11 txns
Insider
Daly Richard J
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 33,500 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 30,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 20,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 15,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 1,365,319 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 491,160 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 381,948 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 126,316 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 40,013 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 115,283 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 271,266 | $31.50 | $8.54M |
Holdings After Transaction:
Options to purchase common stock — 0 contracts (Direct);
Restricted Stock Units — 0 contracts (Direct);
Common Stock, par value $0.001 per share — 0 shares (Direct)
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Common shares disposed: 271,266 shares at $31.50 per share
RSUs cancelled (tranche 1): 115,283 restricted stock units
RSUs cancelled (tranche 2): 40,013 restricted stock units
+5 more
8 metrics
Common shares disposed
271,266 shares at $31.50 per share
Disposition to issuer on July 15, 2026 in connection with merger
RSUs cancelled (tranche 1)
115,283 restricted stock units
Each unit converted into a cash right based on $31.50 per share
RSUs cancelled (tranche 2)
40,013 restricted stock units
Cancelled and converted into cash at the $31.50 merger price
RSUs cancelled (tranche 3)
126,316 restricted stock units
Cancelled and converted into cash at the $31.50 merger price
Options cancelled (series 1)
381,948 options at $22.77 exercise price
Each option cashed out at $31.50 minus $22.77 per share
Options cancelled (series 2)
491,160 options at $21.12 exercise price
Cancelled and converted into cash based on $31.50 merger price
Options cancelled (series 3)
1,365,319 options at $13.30 exercise price
Cancelled and converted into cash at $31.50 less $13.30 per share
Merger cash price
$31.50 per share
Used to determine cash-out value of RSUs and stock options
Key Terms
restricted stock unit, stock option, tax withholdings, exercise price, +1 more
5 terms
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
tax withholdings financial
"cash payment (without interest, and less applicable tax withholdings and other"
exercise price financial
"excess of $31.50 per share over the per-share price of such Option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
contingent right to receive financial
"represents a contingent right to receive one share of the Issuer's common"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Catalyst Pharmaceuticals (CPRX) CEO Richard J. Daly disclose?
Richard J. Daly disclosed disposing of 271,266 common shares, along with all reported RSUs and stock options, on July 15, 2026. These equity awards were cancelled and converted into cash rights in connection with Catalyst Pharmaceuticals’ acquisition by Angelini Pharma S.p.A..
What happened to Richard J. Daly’s RSUs and stock options in CPRX?
All reported restricted stock units and stock options held by Richard J. Daly were cancelled and converted into cash rights tied to a $31.50 merger price. Option payouts equal $31.50 minus the option’s exercise price, multiplied by the number of shares underlying each option.
What merger price was used to cash out Catalyst Pharmaceuticals (CPRX) equity awards?
The equity awards were cashed out using a merger price of $31.50 per share. RSUs were converted into cash at $31.50 per unit, while stock options produced cash equal to $31.50 minus the option exercise price, times the number of underlying shares, before tax withholdings.
Does Richard J. Daly report any remaining RSUs or options in CPRX after the merger?
No remaining holdings of the reported RSUs or stock options are shown after the merger-related transactions. Each reported award either vested in full and was cancelled or was otherwise cancelled and converted into a cash right as part of the Angelini Pharma S.p.A. acquisition.
Were the CPRX CEO’s Form 4 transactions made under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked as an affirmative trading plan. The transactions are described instead as occurring in connection with the consummation of the merger with Angelini Pharma S.p.A., which triggered cash-out of the reported awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
